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Asthma is a complex heterogeneous disease, encompassing
multiple clinical phenotypes. A number of characteristics,
including age at onset, triggering factors, presence of allergic
features, and the nature of the underlying airway inﬂammation,
have been used to distinguish between different asthma pheno-
types.1 This focus on “molecular” phenotypes has aimed at
developing targeted asthma therapies.2 However, identifying
patients with different attitudinal or behavioral characteristics
may also offer the potential for more personalized management.
This is because patients’ attitudes, beliefs, and behaviors can all
impact on their ability to manage and cope with their condition.
New strategies to improve the management of chronic diseases
should, therefore, take these aspects into consideration.3
In asthma, patient-reported outcomes, such as symptoms and
quality of life, correlate strongly with psychosocial measures;
furthermore, socioeconomic factors and psychological states, such
as anxiety, are strongly related to asthma outcomes.4 Indeed, pa-
tients’ attitudes to asthma and medications can inﬂuence treat-
ment adherence, asthma control, and disease outcomes.5-10 There
is potential, therefore, for interventions addressing patients’ atti-
tudes and beliefs to improve adherence and outcomes in asthma.
Indeed, in adults with moderate-to-severe asthma, attitudes
regarding treatments and relationships with medical professionals
predicted future risk of uncontrolled asthma.11 Identifying
different attitudes and personality traits among patients with
asthma thus has the potential to improve their management.
The REcognise Asthma and LInk to Symptoms and Experi-
ence (REALISE) surveys, conducted in Europe and Asia, were
large multicountry appraisals of patient attitudes and behaviors
toward asthma and its management.12,13 The REALISE Europe
survey (N ¼ 8,000) reported that more than 80% of patients
with asthma did not consider themselves “sick,” and many
ignored their asthma to “feel normal and ﬁt in.”12 The levels ofasthma control among respondents were low according to Global
Initiative for Asthma (GINA) criteria,14 with 45.1% having
uncontrolled asthma, but more than 90% of patients considered
their asthma to be controlled. The REALISE Asia survey,
involving more than 2,400 patients with asthma from 8 coun-
tries, reported similar ﬁndings.13 The levels of GINA-deﬁned
asthma control were low (49.7% uncontrolled), and patients’
perceptions of their level of asthma control were overestimated.
Here, we report ﬁndings from a multifactorial cluster analysis
evaluating attitudinal data from the REALISE Europe survey to
further explore patients’ attitudes toward managing their asthma
and the impact of these attitudes toward asthma control.
METHODS
REALISE Europe survey
The REALISE Europe survey was a quantitative, questionnaire-
based survey, conducted online in 11 countries (Austria, Belgium,
Finland, France, Germany, Italy, the Netherlands, Norway, Spain,
Sweden, and the United Kingdom) between July and October 2012.
Full details of the survey design and methodology have been
reported previously, so only a brief overview is provided here.12
Eligible respondents were aged 18 to 50 years, had a physician-
conﬁrmed asthma diagnosis and at least 2 asthma prescriptions in
the previous 2 years, and used social media. The respondents who
had participated in market research surveys within the previous
3 months were excluded.
The current analyses focus on REALISE survey questionnaire re-
sponses regarding patients’ attitudes toward asthma and its manage-
ment. The respondents rated their level of agreement with 34
statements (referred to as attitudinal variables) on a 4-point scale
(“strongly disagree,” “tend to disagree,” “tend to agree,” “strongly
agree”). However, the frequency of using the extremes of the “agree-
disagree” scales varied between countries, suggesting that cultural
factors were biasing the patterns of responses. The response data were,
therefore, dichotomized into simple “agree” or “disagree” categories to
account for these differences. Asthma control was assessed using the 4
GINA 2011 criteria based on responses to questions from the Helping
Asthma in Real-life Patients initiative (how many days in the previous
7 days respondents had day-time symptoms, had awoken at night or
had their normal activities affected by asthma, and how many times
they had used a reliever inhaler).
The survey was led by an independent Steering Committee, and
all analyses were deﬁned a priori. The survey was conducted by
Incite Marketing Planning Limited (London, UK), in accordance
with the Codes of Conduct of the Market Research Society, Euro-
pean Pharmaceutical Marketing Research Association, and Associa-
tion of the British Pharmaceutical Industry, and guidelines from the
British Healthcare Business Intelligence Association. Data were
managed in accordance with the Data Protection Act (UK, 1998).
Data analyses
Factor analysis. Factor analysis consolidated the 34 attitudinal
variables provided by the study population into a set of 8 summary
factors, containing related groups of attitudinal variables (Table I). It
was performed using Statistica version 10 using the principal-
components extraction method. All factors with eigenvalues greater
than 1 were retained (Kaiser’s criteria), and Varimax rotation was
used to aid interpretation.
Cluster analyses. Cluster analyses were used to divide
respondents into groups of patients with similar attitudes and
TABLE I. Results of the factor analysis, showing the related groups of questionnaire statements (attitudinal variables) comprising the
summary factors
Summary factors Attitudinal statements
Impact on activities of daily living* I have to take time off work because of my asthma
My asthma affects my sex life
My asthma affects my work
My asthma makes me feel self-conscious when I want to be intimate with someone
My asthma stops me living life to the full
Socially conscious about asthma* I feel embarrassed using my asthma inhaler in front of others
I feel embarrassed carrying my asthma inhaler around with me
I ignore my asthma and its symptoms so I can feel normal and ﬁt in with my friends/peers
I ﬁnd it a real nuisance having to use my inhaler
Stress in daily life* I often have days where I feel stressed out
If someone asked me, I would say I had a stressful life
If I have a lot of things to do, I can get agitated and cross with people
I often can’t sleep at night, as I am worrying about what happened that day
I wish I had more time to do the things I want to do
Anxious about asthma* I worry about what my asthma will be like in 10 y
I worry about the impact my asthma will have on my health in the future
I am anxious about not knowing when my next asthma attack is coming
I would like to have easier access to prescriptions for my asthma medication
Having to take regular asthma medication worries me
Deprioritizing health* I live for today, rather than worry about tomorrow
I have no time to think about my health, as other things are more important
When my asthma symptoms become worse, it is my own fault
Conﬁdence in doctor† My doctor (or nurse) doesn’t understand my asthma
I have discussed my asthma with my doctor, but it didn’t answer all of the questions I had
I know better than my doctor how to manage my asthma
I ﬁnd my inhaler difﬁcult to use
I ignore my doctor’s instructions about when and how often to take my medication
Asthma dominates life† I know how to manage my asthma without the help of my doctor
I have control over my asthma
My symptoms are not serious
Accepting the asthma label† I see myself as healthy and ﬁt
Don’t label me as a person who is sick
I am not like other people with asthma
I just get on with my life; I don’t think about my asthma
*Individuals who agreed with statements in the factor group received a higher factor score.
†Individuals who disagreed with statements in the factor group received a higher factor score.
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summary factors, minimizing factor differences within a group and
maximizing factor differences between groups. Cluster names were
deﬁned according to the predominant characteristics and behaviors
of patients in each cluster. Potential cluster names were suggested
initially by all 3 authors, who subsequently discussed and reﬁned the
proposed terminology to ensure that a consensus was reached. Of the
8,000 respondents who completed the survey, 7,930 were included
in the cluster analysis. The other 70 respondents were excluded
because they used the same response category across all the attitu-
dinal items; thus their responses were not considered an accurate
reﬂection of attitudes to asthma. Latent class analysis (LCA) was
used for the cluster analysis because it employs statistical (rather than
mathematical) methodology. An ordered categorical regression
model was used to identify signiﬁcant discriminators among the
candidate explanatory variables. Segmentation models with different
numbers of clusters were derived using the LCA, and each respon-
dent was classiﬁed (probabilistically) into one a cluster. The Bayesianinformation criterion (BIC) assessed which models showed the best
ﬁt to the survey response data.
GINA-deﬁned control status was included as a covariate in the
cluster analysis to improve the performance of the segmentation
models. The LCA was performed using the Latent GOLD statistical
package (Statistical Innovations, Belmont, Mass).RESULTS
Survey respondents
The demographic and disease characteristics of the cluster
analysis population (N ¼ 7,930) are shown in Table II. More
than 60% were female, and the mean age was 35 years. The
majority of patients (70.7%) were diagnosed with asthma at least
11 years ago. Fewer than half (43.6%) used a preventer inhaler,
and almost a quarter (23.6%) used a combination inhaler.
Asthma was controlled, partially controlled, or uncontrolled in
20.2%, 35.0%, and 44.8% of patients, respectively.
TABLE II. Demographics and characteristics of the cluster anal-
ysis population




Mean (SD) age (y) 35  9





Years since asthma diagnosis*, n (%)
1 or less 230 (3.3)
2-5 771 (11.0)
6-10 1,059 (15.1)
11 or more 4,974 (70.7)
Current smokers†, n (%) 1,796 (22.6)
Comorbiditiesz, n (%)
Depression 1,781 (22.5)
High BP/hypertension 1,193 (15.0)
Diabetes 861 (10.9)
Rheumatoid arthritis 660 (8.3)
COPD 480 (6.1)
Heart disease 415 (5.2)
Cancer 216 (2.7)
Treatment type, n (%)
Taking preventer inhaler 3,458 (43.6)
Taking reliever inhaler 6,111 (77.1)
Prescribed preventer inhaler 3,458 (43.6)
Prescribed combination inhaler 1,874 (23.6)
Prescribed oral pill 1,810 (22.8)
Other medications 821 (10.4)
No or unknown treatment 782 (9.9)
GINA-deﬁned asthma control, n (%)
Controlled 1,599 (20.2)
Partially controlled 2,778 (35.0)
Uncontrolled 3,553 (44.8)
BP, Blood pressure; COPD, chronic obstructive pulmonary disease; GINA, Global
Initiative for Asthma; SD, standard deviation.
*n ¼ 7034.
†Combines answers for respondents who described themselves as “still smoking,” as
opposed to “never smoked tobacco,” “have tried tobacco in the past, but don’t
currently smoke,” and “used to smoke tobacco, but don’t now.”
zSelf-reported by respondents as having been diagnosed by a doctor, in response to
the question: “Do you currently suffer from any of the following illnesses, which
have been diagnosed by a doctor?”
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The analysis of BIC values showed that model performance
improved as the number of clusters increased from 1 to 5, with a
minimal change with more than 6 clusters. With larger numbers
of clusters, some groups had too few respondents to proﬁle
accurately. As such, 2 segmentation models that divided the
patients into 5 and 6 clusters, respectively, were considered for
further analysis.
Summary factor scores for the 5-cluster analysis are shown in
Figure 1, showing 5 distinct patient clusters that differ in their
attitudes to the summary factors. By contrast, summary factor
scores for the 6-cluster analysis showed that 2 groups ofrespondents (clusters 4 and 5) were similar except for 1 factor.
Moreover, any improvement in the BIC value was minimal
compared with the 5-cluster analysis. The 5-cluster analysis was,
therefore, selected as the best model for the data.
The 5 patient clusters were named according to the attitudes
of patients to the summary factors: “Conﬁdent and self-man-
aging” (cluster 1), “Conﬁdent and accepting of their asthma”
(cluster 2), “Conﬁdent but dependent on others” (cluster 3),
“Concerned but conﬁdent in their health care professional
(HCP)” (cluster 4), and “Not conﬁdent in themselves or their
HCP” (cluster 5).
Cluster 2 contained the largest number of patients, comprising
35% of the overall population (Figure 2). Clusters 1 (26%) and 4
(28%) were similar in size, whereas clusters 3 and 5 were the
smallest (each approximately 5%). The distribution of patients
between groups varied across the 11 countries (Figure 2).
Key patient characteristics for each cluster
Patient demographics and characteristics for each cluster are
shown in Table III. Apart from the “Not conﬁdent in themselves
or their HCP” cluster, there were slightly more female than male
patients in each cluster, and patients were distributed fairly
evenly between the age categories.
“Confident and self-managing” (cluster 1). Patients in
this cluster had the following characteristics: their daily lives were
the least affected by asthma compared with other clusters, and
they were much less anxious or socially conscious about their
condition than the average for the population (Figure 1). They
had high conﬁdence in doctors and were the most independent
when it came to asthma management but were less accepting of
the asthma label.
Cluster 1 patients had the highest conﬁdence in managing
their asthma (98.2% “fairly/very conﬁdent”), were the least
worried about when the next asthma attack was coming, and had
the lowest level of asthma information seeking (Table IV). They
also had the lowest rate of reliever use (50.6% reported no use in
the past 7 days) and a high rate of preventer inhaler use (44.9%;
Table IV). Asthma control was highest in this cluster, with
89.6% of patients either controlled or partially controlled.
“Confident and accepting of their asthma” (cluster
2). This cluster comprised patients whose daily lives were less
affected by asthma than the population average and who were
only slightly more anxious or socially conscious about asthma
than the average (Figure 1). They had higher levels of conﬁdence
in doctors than all other clusters, except cluster 1.
Most considered their asthma to be “not serious” (92.3%) and
had a high level of conﬁdence in managing their asthma (94.4%
“fairly/very conﬁdent”; Table IV). Their asthma concerns were
low, as was the frequency of information seeking about asthma.
Patients in this cluster showed a moderate degree of asthma
control, with 69.5% either controlled or partially controlled
(Table III). Approximately half reported nighttime symptoms or
awakenings as a result of asthma (47.4%) and that asthma
interfered with their daily activities (51.3%; Table IV).
“Confident but dependent on others” (cluster
3). This cluster comprised patients whose daily lives were less
affected by asthma and who were less concerned about asthma
and its treatment than the population average (Figure 1). They
were the least socially conscious about asthma and using inhalers,
–2.0 –1.0 –0.5 0.0 0.5 1.0 1.5 2.0 –2.0 –1.0 –0.5 0.0 0.5 1.0 1.5 2.0
–2.0 –1.0 –0.5 0.0 0.5 1.0 1.5 2.0
–2.0 –1.0 –0.5 0.0 0.5 1.0 1.5 2.0





“Confident and self-managing” (cluster 1) “Confident and accepting of their asthma” (cluster 2)
“Confident but dependent on others” (cluster 3)
“Not confident in themselves or their HCP” (cluster 5) 
“Concerned but confident in their HCP” (cluster 4)
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Deprioritizing health
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Accepting the asthma label
Deprioritizing health
Socially conscious about asthma
Disagree with the factor Agree with the factor Disagree with the factor Agree with the factor
Disagree with the factor Agree with the factor
Disagree with the factor Agree with the factor
Disagree with the factor Agree with the factor
FIGURE 1. Summary factors scores for the individual patient clusters in REALISE Europe based on a 5-cluster analysis. Colored symbols
indicate the scores for each respective cluster; gray symbols indicate the equivalent scores in the other clusters. HCP, Health care
professional.
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on others regarding asthma management.
Cluster 3 patients had the lowest levels of preventer inhaler
use (35.7%) but moderate levels of information seeking aboutasthma (Table IV). Asthma concern levels were low, and
conﬁdence in managing asthma was high. However, these
patients showed only a moderate degree of asthma control,
with 52.5% either controlled or partially controlled.





















N [ 2044 N [ 2782 N [ 442 N [ 2194 N [ 468
Sex, n (%)
Male 689 (33.7) 922 (33.1) 192 (43.4) 986 (44.9) 252 (53.8)
Female 1,355 (66.3) 1,860 (66.9) 250 (56.6) 1,208 (55.1) 216 (46.2)
Age range (y), n (%)
18-25 383 (18.7) 549 (19.7) 100 (22.6) 419 (19.1) 73 (15.6)
26-35 670 (32.8) 912 (32.8) 135 (30.5) 729 (33.2) 216 (46.2)
36-40 347 (17.0) 481 (17.3) 65 (14.7) 388 (17.7) 81 (17.3)
41-50 644 (31.5) 840 (30.2) 142 (32.1) 658 (30.0) 98 (20.9)
GINA-deﬁned asthma control, n (%)
Controlled 975 (47.7) 542 (19.5) 52 (11.8) 20 (0.9) 10 (2.1)
Partially controlled 856 (41.9) 1,392 (50.0) 180 (40.7) 283 (12.9) 67 (14.3)
Uncontrolled 213 (10.4) 848 (30.5) 210 (47.5) 1,891 (86.2) 391 (83.5)





























































0 10 20 30 40 50
Proportion of patients (%)
60 70 80 90 100
UK (n = 996) 
Sweden (n = 599) 
Spain (n = 1010) 
Norway (n = 232) 
Netherlands (n = 849) 
Italy (n = 1005) 
Germany (n = 991) 
France (n = 1015) 
Finland (n = 465) 
Belgium (n = 300) 
Austria (n = 468) 
Overall (n = 7930) 
“Confident and self-managing” (cluster 1)
“Confident and accepting of their asthma” (cluster 2)
“Confident but dependent on others” (cluster 3)
“Not confident in themselves or their HCP” (cluster 5) 
“Concerned but confident in their HCP” (cluster 4)
FIGURE 2. Distribution of patients among the 5 clusters, overall and by country. HCP, Health care professional.
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time awakenings and reported normal activities being affected
by asthma (Table IV), yet only 7% agreed that asthma stopped
them from living life to the full.
“Concerned but confident in their HCP” (cluster
4). These patients were concerned about their asthma but
conﬁdent in their HCP; asthma had a greater impact on them
relative to the overall population, in terms of daily activities and
being anxious and socially conscious about asthma (Figure 1).
These patients were more dependent on others than average interms of asthma management and were the most receptive to the
asthma label.
More than one-third (37.1%) of patients considered their
asthma to be serious, and 51.6% were concerned about their
asthma, both of which were greater than for the other clusters
(Table IV). The frequency of information seeking was high, with
30.5% of patients looking for information about asthma at least
weekly. Conﬁdence in managing asthma was the lowest in this
cluster, with 16.5% not conﬁdent in managing their asthma.
These patients had the lowest level of asthma control, with only
13.8% having controlled or partially controlled asthma.




















N [ 2,044 N [ 2,782 N [ 442 N [ 2,194 N [ 468
Patient perceptions of and information
seeking about asthma
Conﬁdent in managing asthma
Very/fairly 2,007 (98.2) 2,627 (94.4) 407 (92.1) 1,831 (83.5) 399 (85.2)
Not very/not at all 37 (1.8) 155 (5.6) 35 (7.9) 363 (16.5) 69 (14.8)
Perceived seriousness of asthma
Not very/not at all 1,979 (96.8) 2,568 (92.3) 365 (82.6) 1,380 (62.9) 332 (70.9)
Very/fairly 65 (3.2) 214 (7.7) 77 (17.4) 814 (37.1) 136 (29.1)
Concerned about asthma
Not very/not at all 1,985 (97.1) 2,271 (81.6) 357 (80.8) 1,061 (48.4) 267 (57.1)
Very/fairly 59 (2.9) 511 (18.4) 85 (19.2) 1,133 (51.6) 201 (42.9)
Socially conscious about asthma
I ignore my asthma and its symptoms
Disagree* 1,422 (69.6) 1,356 (48.7) 410 (92.8) 1,316 (60.0) 66 (14.1)
Agree† 622 (30.4) 1,426 (51.3) 32 (7.2) 878 (40.0) 402 (85.9)
I feel embarrassed carrying my
inhaler around with me
Disagree* 2,003 (98.0) 2,129 (76.5) 436 (98.6) 1,297 (59.1) 50 (10.7)
Agree† 41 (2.0) 653 (23.5) 6 (1.4) 897 (40.9) 418 (89.3)
I feel embarrassed using my
inhaler in front of others
Disagree* 2,003 (98.0) 2,129 (76.5) 436 (98.6) 1,297 (59.1) 50 (10.7)
Agree† 41 (2.0) 653 (23.5) 6 (1.4) 897 (40.9) 418 (89.3)
Worried about not knowing
when next asthma attack is coming
Disagree* 1,857 (90.9) 1,710 (61.5) 321 (72.6) 865 (39.4) 72 (15.4)
Agree† 187 (9.1) 1,072 (38.5) 121 (27.4) 1,329 (60.6) 396 (84.6)
Information seeking about asthma
At least once a weekz 32 (1.6) 153 (5.5) 63 (14.3) 669 (30.5) 240 (51.3)
Monthly to yearlyx 483 (23.6) 1,080 (38.8) 169 (38.2) 926 (42.2) 162 (34.6)
Less than once a year 520 (25.4) 609 (21.9) 65 (14.7) 226 (10.3) 29 (6.2)
None (“I don’t look for information”) 1,009 (49.4) 940 (33.8) 145 (32.8) 373 (17.0) 37 (7.9)
Indicators of asthma symptoms
and preventer inhaler use
Nighttime symptoms/awakenings*
None 1,576 (77.1) 1,462 (52.6) 167 (37.8) 371 (16.9) 53 (11.3)
1 d 468 (22.9) 1,320 (47.4) 275 (62.2) 1,823 (83.1) 415 (88.7)
Days with symptomsk
None 862 (42.2) 548 (19.7) 90 (20.4) 85 (3.9) 29 (6.2)
1 d 1,182 (57.8) 2,234 (80.3) 352 (79.6) 2,109 (96.1) 439 (93.8)
3 d 286 (14.0) 883 (31.7) 189 (42.8) 1,616 (73.7) 321 (68.6)
Normal activities affected by symptoms*
None 1,570 (76.8) 1,354 (48.7) 173 (39.1) 210 (9.6) 44 (9.4)
1 d 474 (23.2) 1,428 (51.3) 269 (60.9) 1,984 (90.4) 424 (90.6)
Preventer inhaler use
Yes 917 (44.9) 1,180 (42.4) 158 (35.7) 1,015 (46.3) 188 (40.2)
(continued)
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5). This category comprised patients who were the most
affected by asthma in their daily activities, who experienced thegreatest psychological burden, who were the most anxious about
their asthma, and who were the most socially conscious about





















N [ 2,044 N [ 2,782 N [ 442 N [ 2,194 N [ 468
No 1,057 (51.7) 1,402 (50.4) 226 (51.1) 956 (43.6) 211 (45.1)
Don’t know 70 (3.4) 200 (7.2) 58 (13.1) 223 (10.2) 69 (14.7)
Reliever inhaler usek
None 981 (50.6) 860 (32.6) 95 (22.9) 175 (8.2) 2,137 (28.2)
1 time 959 (49.4) 1,780 (67.4) 319 (77.1) 1,957 (91.8) 431 (94.3)
3 times 420 (21.6) 881 (33.4) 202 (48.8) 1,536 (72.0) 3,378 (44.5)
10 times 69 (3.6) 129 (4.9) 35 (8.5) 263 (12.3) 511 (6.7)
Data are shown as the number of patients (%).
HCP, Health care professional.
*Strongly disagree or tend to disagree.
†Strongly agree or tend to agree.
zIncludes the categories “several times a day,” “every day,” “2 to 5 times a week,” and “every week.”
xIncludes the categories “1 or 2 times a month,” “every 3 mo,” “every 6 mo,” and “every year.”
kIn the previous 7 d.
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deprioritized their health to a much greater extent than the
overall population and were more independent than average
when it came to asthma management. They had the least con-
ﬁdence in doctors of all the clusters.
Cluster 5 patients perceived their asthma to be serious, and
conﬁdence in managing their disease was low (Table IV).
Preventer inhaler use was the second lowest among the clusters
(40.2%), and most patients (84.6%) were worried about when
the next asthma attack was coming. Information seeking was
high, with 51.3% searching for asthma information at least
weekly. Asthma control was low, with only 16.4% either
controlled or partially controlled.DISCUSSION
This analysis of the REALISE Europe survey results showed
that patients with asthma can be divided into 5 distinct clusters
based on their attitudes toward 8 aspects of asthma and its
management. Because the survey was administered online, and
all respondents were active on “social media,” the data reﬂect the
attitudes of a “new era” of patients with asthma likely to be
receptive to multiple sources of information about their
condition.
A similar analysis of the attitudes of adult Asian patients with
asthma was performed using data from the REALISE Asia survey
(8 countries, N ¼ 2,467).15 Information was collected using an
online questionnaire and analyzed using the same 2-stage
methodology as the European data. Factor analysis reduced the
27 Asian attitudinal variables to 9 summary factors, and cluster
analysis identiﬁed 5 distinct groups that had clear similarities to
the European clusters, although some differences were
apparent.15 Both analyses identiﬁed a cluster whose patients had
high levels of asthma control; high levels of conﬁdence in
managing asthma; low perceptions about asthma severity,
concern, and social consciousness; and low information-seeking
behavior (cluster 1). Likewise, the “Worried with multiple
symptoms” cluster from the Asian analysis was similar to the
European “Concerned but conﬁdent in their HCP” cluster, andthere were strong similarities between the “Adrift and poorly
controlled” (Asia) and “Not conﬁdent in themselves or their
HCP” (Europe) clusters. Similarities were also observed between
the Asian “In denial about symptoms” and European “Conﬁdent
and accepting of their asthma” clusters.15 Together, these ﬁnd-
ings provide clear evidence that opportunities exist for manage-
ment approaches to be tailored according to the beliefs and
behaviors of each cluster, to help improve disease awareness,
management, and control.
Another cluster analysis of adults with asthma taking main-
tenance medications conducted in the United States identiﬁed 5
distinct groups of patients based on their illness perception and
medication beliefs.16 Individuals in 2 of these clusters were
adherent, whereas those in the other 3 clusters were non-
adherent. Adherent clusters were accepting of their illness and
had strong beliefs in the necessity of medication, and concerns
about its use were low. The nonadherent clusters were catego-
rized as “indifferent,” “ambivalent,” and “skeptical,” based on
attitudes toward the need for medication, concerns about its use,
and perceptions about their illness. As with adherent patients,
nonadherent patients with few concerns had well-controlled
asthma, whereas those with strong concerns had uncontrolled
asthma. This association between negative patient attitudes and
poor outcomes strongly suggests that targeted interventions need
to consider more than just the clinical characteristics of a
patient.16
Our analysis of the REALISE Europe data shows how this
“new era” of patients who are active on social media also tend to
exhibit distinct behavioral types. Patients in different clusters
may require different approaches and have different needs; hence
HCPs will need to communicate and engage effectively with each
type to better manage their asthma. The clusters with the lowest
GINA-deﬁned asthma control, “Concerned but conﬁdent in
their HCP” and “Not conﬁdent in themselves or their HCP,”
may be key groups for HCP intervention. For example, patients
in the “Concerned but conﬁdent in their HCP” cluster had high
levels of information-seeking behavior and conﬁdence in their
HCP. Thus, there is an opportunity to help these patients gain
better asthma control and relieve their concerns by providing
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and reviewing their medication. In the “Not conﬁdent in
themselves or their HCP” cluster, patients were anxious and
worried about when they might have an asthma attack, sug-
gesting a need to build conﬁdence in managing their asthma by
providing trustful and frequent support. More than half of
patients in this cluster searched for asthma information at least
weekly, meaning more could be done to build trust in their HCP
and to help them accept that they have asthma while reducing
their concerns about social stigma and overall anxiety. In the
“Conﬁdent but dependent on others” cluster, patients were not
anxious or information-seeking, yet despite having conﬁdence in
managing their disease, they were dependent on their doctor.
Nearly half of patients in this cluster had uncontrolled asthma,
suggesting that more HCP-guided education and empowerment
may improve self-management and asthma control while
reducing reliance on their doctor.
Several studies have shown how personality traits and medi-
cation beliefs can affect treatment adherence, outcomes, and
quality of life in patients with asthma.5-10 Patients’ beliefs in their
own ability and the ability of treatments to control asthma
symptoms, and viewing asthma as a chronic illness that requires
maintenance medication, have been associated with good out-
comes and quality of life.6 By contrast, negative beliefs about the
potential for asthma control and the perception that asthma is an
episodic disease with few adverse consequences have all been
associated with reduced treatment adherence.5 Patients’ beliefs
about asthma medication also affect treatment adherence, with
positive beliefs associated with improved adherence, and negative
concerns linked with reduced adherence.7-9 In one study in
adults with asthma, 3 particular personality traits were more
likely to be associated with poor adherence than other traits, and
individuals with these traits also showed increased concerns
about asthma medication.17 Interventions speciﬁcally aimed at
addressing medication concerns in these patients, such as shared
decision making, individualizing treatment choice, and tailoring
education, could therefore have a beneﬁcial effect on adher-
ence.18-20
However, the challenge remains regarding how to identify
which attitudinal cluster a patient belongs to. One possibility is
for HCPs to explore patient attitudes and beliefs during con-
sultations and use these responses to judge which cluster a patient
corresponds to. Patient-centered techniques, such as those
drawing on motivational interviewing principles developed for
adherence counseling, can help HCPs to ascertain the views,
beliefs, and concerns a patient may have about asthma and its
medication.21 A short validated questionnaire or online proﬁling
tool that patients complete in advance of a consultation could
also be developed, which automatically calculates which cluster a
patient belongs to.
One such tool was developed recently by an international
expert panel during a 3-round Delphi consensus study exploring
the REALISE Asia survey results.22 They created an Asthma
Patient Proﬁling Tool, comprising 10 short questions to which
the patient responds “Agree/Disagree.” The HCP also indicates
whether the patient has controlled, partly controlled, or uncon-
trolled asthma, and an attitudinal classiﬁcation is generated
automatically. The expert panel also proposed pharmacological
and nonpharmacological recommendations tailored to eachcluster, and a Management Pathway Algorithm illustrating how
to best implement each recommendation.22 However, the tool
was only developed very recently and as such is yet to be vali-
dated; also, patients were not involved during its design.22 Thus,
it currently remains unknown to what extent the tool may
improve the management of patients in real-world settings.
Likewise, the authors of the US cluster analysis took into
consideration the different beliefs and perceptions of patients in
each cluster before proposing different potential intervention
strategies to improve adherence in the nonadherent groups.16 A
similar approach could be applied to the current cluster analysis
from the REALISE Europe survey to develop tailored strategies
for European patients, although any such instruments would
take time to develop, test, and validate before being imple-
mented. There may be practical challenges associated with
implementing these interventions into daily clinical practice,
given the increasing time and resource pressures facing HCPs. It
is important that any tools developed to assist with imple-
mentation are readily accessible and easy to use.
A limitation of this study arises from its online survey-based
design. Any analysis based on survey and online responses
carries a potential inherent bias, in that the sample population
comprises only those individuals able and willing to respond.
Therefore, the phenotypes identiﬁed in the analysis and the
relative numbers of individuals classiﬁed into these phenotypes
may not be representative of the full asthma population and
generalizable to all patients. Also, the analyses are correlative and
so do not prove a causal link between the clusters and asthma
control. Finally, naming of the clusters was deﬁned according to
the predominant characteristics and behaviors of patients in each
cluster, but was done subjectively by the authors. The names
were discussed and reﬁned by all 3 authors to ensure that a
consensus was reached.
In conclusion, analyses of data from the REALISE Europe
survey have identiﬁed 5 distinct attitudinal clusters of patients
who may have different clinical needs, and require different
approaches to optimize their asthma management. Future
research should focus on examining how these ﬁndings can be
applied to clinical practice, in terms of how to determine quickly
and accurately which cluster a patient belongs to and how
interventions can be tailored accordingly.
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